批判性评估颊黏膜移植尿道成形术后抗生素的作用:一项索赔数据库分析
本研究基于TriNetX索赔数据库开展回顾性队列研究,纳入2008-2022年接受初次颊黏膜移植尿道成形术的884例患者,比较术后使用与不使用抗生素者的结局。结果显示两组5年翻修率及围手术期感染并发症均无显著差异,术后抗生素未见显著获益。
要点
- 颊黏膜移植尿道成形术后使用抗生素组占81%,未使用组占19%。
- 两组5年内镜翻修率、再行尿道成形术率及全因翻修率均无显著差异。
- 两组术后尿路感染、手术部位感染及艰难梭菌感染发生率相似。
核心结论
- 在这项大型回顾性队列研究中,颊黏膜移植尿道成形术后使用抗生素对长期翻修率或围手术期感染并发症未见显著获益。
研究设计与样本
- 回顾性队列研究,使用TriNetX索赔数据库2008-2022年数据,纳入年龄>18岁接受初次颊黏膜移植尿道成形术且术后第0-30天有门诊抗生素处方或无处方的患者,排除术前尿培养阳性或术前30天内尿路感染者,共884例(抗生素组81%,非抗生素组19%)。
主要发现
- 两组5年内镜翻修率分别为11.5%与9.5%(RR 1.2,95% CI [0.7, 2.0],无复发生存log-rank P=0.6),无显著差异。
- 两组5年再行尿道成形术率分别为12.9%与13.7%(RR 0.9,95% CI [0.6, 1.5],无复发生存log-rank P=0.7),无显著差异。
- 两组5年全因翻修率分别为19.8%与17.7%(RR 1.1,95% CI [0.8, 1.6],P=0.5),无显著差异。
- 两组术后30天内尿路感染、90天内手术部位感染及30天内艰难梭菌感染发生率相似。
关键数值与推荐
- 内镜翻修:抗生素组11.5% vs 非抗生素组9.5%,RR 1.2,95% CI [0.7, 2.0],log-rank P=0.6。
- 再行尿道成形术:抗生素组12.9% vs 非抗生素组13.7%,RR 0.9,95% CI [0.6, 1.5],log-rank P=0.7。
- 全因翻修:抗生素组19.8% vs 非抗生素组17.7%,RR 1.1,95% CI [0.8, 1.6],P=0.5。
临床怎么用
- 原文结论未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To compare outcomes among patients undergoing first-time urethroplasty with buccal mucosa graft (BMG) who receive postoperative antibiotics vs those who do not. METHODS: A retrospective cohort study was conducted using the TriNetX claims database between 2008-2022. Using CPT, ICD10, and LOINC codes, patients >18 years old undergoing primary urethroplasty with BMG who received an outpatient prescription for antibiotics between postoperative day 0-30 or did not were queried. Patients with positive preoperative urine culture or urinary tract infection (UTI) within 30days preoperatively were excluded. Surgical outcomes included 5-year revision rates and revision-free survival. Safety outcomes included new UTI within 30days, surgical site infection within 90days, or Clostridium difficile infection within 30days of urethroplasty. RESULTS: We identified 884 patients (81% antibiotic cohort, 19% nonantibiotic cohort) that met inclusion criteria. Age at time of urethroplasty, suprapubic tube presence, and pre-existing medical comorbidities were comparable between cohorts (Table 1A). There was no difference in 5-year rates and revision-free survival for endoscopic revision (11.5% vs 9.5%, relative risk (RR) 1.2, 95% CI [0.7, 2.0], recurrence-free survival (RFS) log-rank P = .6), re-do urethroplasty (12.9% vs 13.7%, RR 0.9, 95% CI [0.6, 1.5], RFS log-rank P = .7), or all-cause revision (19.8% vs 17.7%, RR 1.1, 95% CI [0.8, 1.6], P = .5) between groups. Postoperative rates of UTI, surgical site infection, and C difficile infection were similar between groups. CONCLUSION: In this large retrospective cohort study of patients undergoing urethroplasty with BMG, we observed no significant benefit from use of postoperative antibiotics on long-term revision rates or perioperative infectious complications.
引用
- Galansky L, Gabrielson AT, Cohen AJ, et al. Critically Evaluating the Role for Postoperative Antibiotics in Patients Undergoing Urethroplasty With Buccal Mucosa Graft: A Claims Database Analysis. Urology. 2024. PMID: 38677376. doi:10.1016/j.urology.2024.03.036
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。